Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Background Limited data exist regarding the population-based epidemiology of idiopathic
pulmonary fibrosis (IPF). The objective of the study was to describe the trends in the …

Idiopathic pulmonary fibrosis (IPF), also known as cryptogenic fibrosing alveolitis, is a
distinct form of interstitial lung disease of unknown etiology that is limited to the lung; it is …

As seen in this CME online activity (available at http://courses. elseviercme. com/694),
idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrotic lung …

Idiopathic pulmonary fibrosis (IPF) is a devastating illness for which current therapy is
minimally effective. If medical therapy for IPF is going to improve over the next decade …

Background The antifibrotic drugs nintedanib and pirfenidone reduce disease progression
in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching …

1. Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE. Prognosis of idiopathic
pulmonary fibrosis without anti-fibrotic therapy: a systematic review. Eur Respir Rev 2020; …

The American Thoracic Society and European Respiratory Society guidelines for the
diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) have been published recently …

Background There is a debate that older patients with idiopathic pulmonary fibrosis (IPF)
have a worse prognosis. We evaluated whether age affects the survival of patients with IPF …

BACKGROUND: The consensus statement on the Diagnosis and Therapy of Idiopathic
Pulmonary Fibrosis (IPF) formulated by the American Thoracic Society/European …